News stories about PetIQ (NASDAQ:PETQ) have been trending somewhat positive on Saturday, according to Accern Sentiment Analysis. The research firm ranks the sentiment of news coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. PetIQ earned a news sentiment score of 0.13 on Accern’s scale. Accern also assigned news articles about the company an impact score of 47.876388214676 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
Here are some of the news articles that may have impacted Accern Sentiment Analysis’s analysis:
Several equities research analysts recently commented on PETQ shares. Jefferies Group reaffirmed a “buy” rating and issued a $27.00 price objective on shares of PetIQ in a research report on Monday, January 8th. Zacks Investment Research cut shares of PetIQ from a “strong-buy” rating to a “hold” rating in a research report on Friday, January 12th. Finally, BidaskClub cut shares of PetIQ from a “buy” rating to a “hold” rating in a research report on Wednesday, February 14th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $27.50.
PETQ traded down $0.87 during trading on Friday, hitting $23.23. The company had a trading volume of 430,153 shares, compared to its average volume of 566,356. The stock has a market capitalization of $564.86 and a P/E ratio of 59.56. PetIQ has a one year low of $17.03 and a one year high of $28.23. The company has a current ratio of 5.99, a quick ratio of 3.56 and a debt-to-equity ratio of 0.17.
In related news, CEO Mccord Christensen sold 40,000 shares of the business’s stock in a transaction on Monday, March 19th. The shares were sold at an average price of $24.92, for a total value of $996,800.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO John Newland sold 5,500 shares of the business’s stock in a transaction dated Monday, March 19th. The stock was sold at an average price of $24.83, for a total transaction of $136,565.00. The disclosure for this sale can be found here. Insiders sold a total of 65,500 shares of company stock worth $1,657,765 over the last ninety days.
TRADEMARK VIOLATION WARNING: “Somewhat Favorable News Coverage Somewhat Unlikely to Affect PetIQ (PETQ) Stock Price” was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this report on another publication, it was stolen and republished in violation of U.S. & international copyright and trademark legislation. The correct version of this report can be viewed at https://www.dispatchtribunal.com/2018/04/07/somewhat-favorable-news-coverage-somewhat-unlikely-to-affect-petiq-petq-stock-price.html.
PetIQ, Inc is engaged in manufacturing and distributing pet medication and health and wellness products to the retail channel in the United States. The Company provides retail stores with third-party brands, including Frontline Plus, Heartgard Plus, PetAction Plus, Advecta II, Pet Lock Plus, Pet Lock Max, TruProfen and Heartshield.
Receive News & Ratings for PetIQ Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PetIQ and related companies with MarketBeat.com's FREE daily email newsletter.